Albumedix Ltd

Albumedix logo

Albumedix - Dedicated to Better Health

Albumedix is a science-driven, life-science company focused on enabling the creation of advanced therapies and biopharmaceuticals utilizing our high quality recombinant human albumin products and technologies. We believe in empowering excellence to enable advanced therapies and facilitate otherwise unstable drug candidates reach patients worldwide. We are proud to be recognized as the world leader in recombinant human albumin with products and technologies used in clinical and marketed drugs by pharmaceutical and medical device companies worldwide. Headquartered in Nottingham, England with more than 100 people all committed to improving patient quality of life. We are just as passionate about albumin and albumin-enabled therapies today as we were when we started more than 35 years ago.

Our vision is to empower excellence in how we as a business operate and create products and services of the highest quality; but also to enable our customers and partners to excel in the development of transformative therapies, and thereby support life sciences and patients equally. As an example, we are proud to be working with domestic, national and international life science companies in these challenging times towards the urgent response against covid-19 - be it diagnostically, therapeutically and prophylactically.

Contact Albumedix via their website

News Archive

24/06/2021   Albumedix extends research collaboration with Cobra Biologics...more
02/02/2021   Albumedix enters into collaboration agreement with Cell and Gene Therapy Catapult...more

24/11/2020   Albumedix CEO Reflects on Bio Integrates 2020...more
18/11/2020   Albumedix CEO contributes to PharmaVOICE 2021 Year in Preview...more

01/08/2018   Albumedix announces evaluation agreement with Novartis...more
26/06/2018   iNANO & Albumedix announce strategic research collaboration for Albumin carrier...more

17/10/2017   Albumedix Establishes Scientific Advisory Board...more
02/10/2017   Albumedix signs agreement with Oslo University Hospital and University of Oslo...more
17/05/2017   Albumedix will host a webinar titled: When Standard Formulation Strategies Fail...more
04/01/2017   Albumedix CEO will present a corporate overview at J.P. Morgan conference...more
04/01/2017   Albumedix Appoints Chief Medical Officer...more

19/12/2016   Nature Communications: Albumedix and collaborators publish new data...more
06/12/2016   Albumedix research agreement with New York University School of Medicine...more
17/05/2016   Albumedix Agreement with Hebei Changshan Biochem Pharma for Diabetes Treatment...more
12/05/2016   Albumedix™ Proprietary VELTIS® Drug Delivery Technology Approved In The EU...more
15/03/2016   Albumedix Technology used by CSL Behring for Haemophilia B in the US ...more
16/02/2016   Albumedix Announces Exclusive Commercialization Agreement with ThioLogics...more
28/01/2016   Eleven Biotherapeutics and Albumedix Announce Agreement...more
19/01/2016   Novozymes separates its biopharma activities to form independent company...more

19/05/2015   Serendex Pharmaceuticals to initiate trials with Novozymes Biopharma stabilizer...more

22/12/2014   Novozymes Biopharma enters license agreement with EpiVax...more
11/12/2014   Novozymes Biopharma published in Expert Opinion on Drug Delivery...more
05/11/2014   Novozymes Biopharma signs Chinese distribution agreement ...more
29/05/2014   Novozymes Biopharma enters new research agreement with top vaccine company...more
12/05/2014   Novozymes Biopharma announces new collaboration with ThioLogics...more
24/04/2014   Novozymes’ half-life extension technology reaches landmark milestone...more
31/03/2014   Novozymes Biopharma technology used by GlaxoSmithKline in type 2 diabetes drug...more
13/03/2014   Novozymes Biopharma announces collaboration with Janssen...more
21/01/2014   Novozymes Biopharma announces new data on extending serum albumin half-life...more

23/10/2013   Novozymes Biopharma announces collaboration with Almac ...more
18/07/2013   Novozymes Biopharma announce new findings concerning the effect of Hyaluronic Acid...more
29/05/2013   Novozymes Biopharma to showcase world leading products at CPhI China...more
20/05/2013   Novozymes Biopharma helps innovative dry eye therapy move into clinical trials...more
27/02/2013   Novozymes Biopharma's rAlbumin approved in Japan...more
13/02/2013   Novozymes Biopharma announces research agreement with EpiVax...more

21/12/2012   Novozymes aligns recombinant human albumin portfolio with new brand name...more
18/05/2012   Novozymes Biopharma Innovation 2012 award win...more
09/05/2012   Novozymes starts commercial supply of hyaluronic acid from Q7 cGMP facility...more
02/05/2012   Novozymes´ rAlbumin supports faster time to market for Neomend product...more